BioSig Technologies Inc (NASDAQ:BSGM) VP of Clinical Affairs Julie Stephenson tells Proactive the Westport, Connecticut-based group has completed enrollment in the PURE EP 2.0 clinical trial. Julie Stephenson says the PURE EP System was used in all types of arrhythmia cases, including atrial fibrillation, ventricular tachycardia, and atrial flutter. It expects to publish the full clinical study results in leading industry publications in the second half of 2021.
BioSig Technologies completes enrollment in its PURE EP 2.0 clinical trial
